Filing Flows › Immucell (ICCC) › Operating margin
Immucell (ICCC) operating margin by quarter
Immucell's operating margin was 26.9% in Q2 2026 (second quarter 2026), +7.9 pts from Q1 2026. Over the last 5 quarters it ranged from 8.0% (Q4 2024) to 26.9% (Q2 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | 26.9% | +7.9 pts | +18.1 pts |
| Q1 2026 | 19.0% | +10.2 pts | +5.2 pts |
| Q2 2025 | 8.8% | -5.0 pts | — |
| Q1 2025 | 13.9% | +5.8 pts | — |
| Q4 2024 | 8.0% | — | — |
Q2 2026 at a glance
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Immucell's operating margin?
Immucell's operating margin was 26.9% in Q2 2026 (second quarter 2026), +7.9 pts from Q1 2026.
How has Immucell's operating margin changed?
Over the last 5 quarters it ranged from 8.0% (Q4 2024) to 26.9% (Q2 2026).